Results with new software for plateletpheresis systems.

Area of Science:

• Hematology
• Biomedical Engineering
• Medical Device Technology

Background:

• Advancements in cell separation technology are crucial for optimizing blood component collection.
• Baxter and Fresenius have introduced new software and single-needle options for their apheresis devices.
• Evaluating the performance of these updates is essential for clinical application.

Purpose of the Study:

• To assess the impact of new software versions on Baxter A 201 and CS 3000 Plus cell separators.
• To evaluate the performance of the Fresenius AS 104 with a single-needle option.
• To compare total platelet yield, separation efficiency, and cell contamination across different devices and protocols.

Main Methods:

• Software versions 5.12 and 5.13 for the Baxter A 201 were tested.
• The Baxter CS 3000 Plus was evaluated.
• The Fresenius AS 104 with a single-needle option was tested using protocols IV and V.

Main Results:

• Baxter A 201: Software version 5.13 yielded more platelets (2.3 x 10^11) with higher efficiency (34.7%) and lower leukocyte contamination (4.9 x 10^8) compared to version 5.12.
• Baxter CS 3000 Plus: Achieved 2.9 x 10^11 platelets with 38.4% efficiency and very low white blood cell contamination (1.4 x 10^6).
• Fresenius AS 104: Demonstrated high separation efficacy (58.7-59.1%) with 3.1 x 10^11 platelets collected.

Conclusions:

• New software for Baxter cell separators enhances platelet collection and reduces contamination.
• The Fresenius single-needle procedure shows high separation efficacy.
• These technological improvements contribute to more efficient apheresis and platelet concentrate production.